You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR Gene Mutation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Nintedanib, gefitinib, erlotinib, afatinib
  • (no location specified)
Oct 2, 2023

NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

Recruiting
  • NSCLC
  • EGFR Gene Mutation
  • neo-antigen vaccine
  • Nanjing, China
    The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
Oct 19, 2023

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)

Recruiting
  • Lung Adenocarcinoma Stage III
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Aug 13, 2022

Lung Cancer, EGFR Gene Mutation, EGFR Trial in Charlottesville (Sensus Smartwatch Application, RX Cap, Fitbit Sense)

Recruiting
  • Lung Cancer
  • +3 more
  • Sensus Smartwatch Application
  • +3 more
  • Charlottesville, Virginia
    University of Virginia
Aug 26, 2022

Lung Adenocarcinoma Stage III, EGFR Gene Mutation Trial in Shang'ai (Afatinib)

Recruiting
  • Lung Adenocarcinoma Stage III
  • EGFR Gene Mutation
  • Shang'ai, Shanghai, China
    Shanghai Pulmonary Hospital
Mar 27, 2022

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Moscow, Russian Federation
      Federal State Budgetary Institution National Medical Research Ce
    Mar 29, 2022

    Lung Cancer Metastatic, EGFR Gene Mutation Trial in San Francisco (Osimertinib, Alisertib)

    Recruiting
    • Lung Cancer Metastatic
    • EGFR Gene Mutation
    • San Francisco, California
      University of California, San Francisco
    Aug 10, 2022

    Double-dose Furmonertinib in Treatment of Slow

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +3 more
    • (no location specified)
    Oct 31, 2023

    Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor Trial in Jerusalem (concomitant TTFields treatment

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
    • concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
    • Jerusalem, Israel
      Shaare Zedek Medical Center
    Jan 22, 2023

    Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative Trial in

    Completed
    • Activating ALK Gene Mutation Negative
    • +7 more
    • Counseling
    • +2 more
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Sep 7, 2022

    Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation Trial in Changsha (Gemcitabine platinum combined with erlotinib)

    Recruiting
    • Carcinoma, Non-Small Cell Lung
    • EGFR Gene Mutation
    • Gemcitabine platinum combined with erlotinib
    • Changsha, Hunan, China
      Hunan Province Tumor Hospital
    Feb 28, 2022

    c-MET Expression and EGFR Gene Mutation Correlation With

    Completed
    • Non-small Cell Lung Cancer Metastatic
    • Non-small Cell Lung Cancer Recurrent
      • Hwasun, Korea, Republic of
        Chonnam National University Hwasun Hospital
      Aug 1, 2021

      Non-squamous NSCLC, EGFR Gene Mutation Trial in Chengdu (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

      Not yet recruiting
      • Non-squamous Non-small Cell Lung Cancer
      • EGFR Gene Mutation
      • Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed
      • Chengdu, Sichuan, China
      • +2 more
      May 24, 2022

      EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

      Recruiting
      • EGFR Exon 20 Mutation
      • +3 more
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 12, 2022

      Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

      Recruiting
      • Lung Neoplasm
      • +26 more
      • Boston, Massachusetts
      • +6 more
      Jun 23, 2022

      Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI

      Recruiting
      • Non-Small Cell Carcinoma of Lung, TNM Stage 4
      • +5 more
        • Aurora, Colorado
          University of Colorado, Cancer Center
        Nov 3, 2021

        Learn About Tests Looking forGene Mutation in Lung Cancer in

        Not yet recruiting
        • Non-small Cell Lung Cancer (NSCLC)
        • No Intervention
        • Beijing, China
          Department of Pathology, National Cancer Center/National Clinica
        Feb 24, 2023

        Lung Tumors, EGFR Gene Mutation Trial in Hwasun (Afatinib)

        Completed
        • Lung Neoplasms
        • EGFR Gene Mutation
        • Hwasun, Jeonnam, Korea, Republic of
          Chonnam National University Hwasun Hospital
        Aug 1, 2021

        EGFR Gene Mutation, Nonsmall Cell Lung Cancer Trial in Washington, Hackensack (Dasatinib, Osimertinib)

        Active, not recruiting
        • EGFR Gene Mutation
        • Nonsmall Cell Lung Cancer
        • Washington, District of Columbia
        • +1 more
        Jan 9, 2022

        Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial in Changsha (Genomic profiles detection,

        Recruiting
        • Lung Cancer, Non-small Cell
        • +4 more
        • Genomic profiles detection
        • circulating tumor DNA detection
        • Changsha, Hunan, China
          Department of Oncology, The Second Xiangya Hospital, Central Sou
        Oct 25, 2022

        NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

        Not yet recruiting
        • Non-Small Cell Lung Cancer
        • Telisotuzumab Vedotin
        • +4 more
        • (no location specified)
        Oct 17, 2023

        Non Small Cell Lung Cancer, Advanced Solid Tumor Trial in France (EGFR gene mutation analysis on liquid biopsy)

        Recruiting
        • Non Small Cell Lung Cancer
        • Advanced Solid Tumor
        • EGFR gene mutation analysis on liquid biopsy
        • Angers, France
        • +8 more
        Feb 2, 2022

        PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

        Recruiting
        • Non Small Cell Lung Cancer
          • Changsha, Hunan, China
            Yongchang Zhang
          Mar 9, 2022

          Lung Cancer, EGFR Gene Mutation Trial (Almonertinib)

          Not yet recruiting
          • Lung Cancer
          • EGFR Gene Mutation
          • (no location specified)
          May 6, 2021